1. A Double‐Blind, Placebo‐Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine. Issue 1 (23rd October 2014) Authors: Cady, Roger; Saper, Joel; Dexter, Kent; Manley, Heather R. Journal: Headache Issue: Volume 55:Issue 1(2015) Page Start: 101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine. (September 2015) Authors: Cady, Roger Journal: Expert opinion on drug delivery Issue: Volume 12:Number 9(2015:Sep.) Page Start: 1565 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. An Exploratory Study of Salivary Calcitonin Gene‐Related Peptide Levels Relative to Acute Interventions and Preventative Treatment With OnabotulinumtoxinA in Chronic Migraine. Issue 2 (22nd October 2013) Authors: Cady, Roger; Turner, Ira; Dexter, Kent; Beach, M. E.; Cady, Ryan; Durham, Paul Journal: Headache Issue: Volume 54:Issue 2(2014) Page Start: 269 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Content Validity of HIT‐6 as a Measure of Headache Impact in People With Migraine: A Narrative Review. Issue 1 (6th December 2019) Authors: Houts, Carrie R.; Wirth, R.J.; McGinley, James S.; Gwaltney, Chad; Kassel, Eric; Snapinn, Steven; Cady, Roger Journal: Headache Issue: Volume 60:Issue 1(2020) Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT‐6) Total and Item‐Specific Scores in Chronic Migraine. Issue 9 (30th August 2020) Authors: Houts, Carrie R.; Wirth, R. J.; McGinley, James S.; Cady, Roger; Lipton, Richard B. Journal: Headache Issue: Volume 60:Issue 9(2020) Page Start: 2003 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. (31st March 2020) Authors: Lipton, Richard B.; Goadsby, Peter J.; Smith, Jeff; Schaeffler, Barbara A.; Biondi, David M.; Hirman, Joe; Pederson, Susan; Allan, Brent; Cady, Roger Journal: Neurology Issue: Volume 94:Number 13(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2. (July 2022) Authors: Ashina, Messoud; McAllister, Peter; Cady, Roger; Hirman, Joe; Ettrup, Anders Journal: Cephalalgia Issue: Volume 42:Number 8(2022) Page Start: 696 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: Subgroup analysis of PROMISE‐2. Issue 1 (13th December 2020) Authors: Diener, Hans‐Christoph; Marmura, Michael J.; Tepper, Stewart J.; Cowan, Robert; Starling, Amaal J.; Diamond, Merle L.; Hirman, Joe; Mehta, Lahar; Brevig, Thomas; Sperling, Bjørn; Cady, Roger Journal: Headache Issue: Volume 61:Issue 1(2021) Page Start: 125 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies. (11th October 2022) Authors: Baker, Brian; Shen, Vivienne; Cady, Roger; Ettrup, Anders; Larsen, Frank Journal: Cephalalgia reports Issue: Volume 5(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. Issue 10 (9th November 2020) Authors: Dodick, David W.; Gottschalk, Christopher; Cady, Roger; Hirman, Joe; Smith, Jeff; Snapinn, Steve Journal: Headache Issue: Volume 60:Issue 10(2020) Page Start: 2220 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗